Toll Free: 1-888-928-9744

Acute Heart Failure - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acute Heart Failure - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Acute Heart Failure - Pipeline Review, H2 2016', provides an overview of the Acute Heart Failure pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Heart Failure and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure
- The report reviews pipeline therapeutics for Acute Heart Failure by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Acute Heart Failure therapeutics and enlists all their major and minor projects
- The report assesses Acute Heart Failure therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Acute Heart Failure

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Acute Heart Failure
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Acute Heart Failure Overview 7 Therapeutics Development 8 Pipeline Products for Acute Heart Failure - Overview 8 Acute Heart Failure - Therapeutics under Development by Companies 9 Acute Heart Failure - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Acute Heart Failure - Products under Development by Companies 13 Acute Heart Failure - Companies Involved in Therapeutics Development 14 Amgen Inc. 14 Capricor Therapeutics, Inc. 15 Eli Lilly and Company 16 Lee's Pharmaceutical Holdings Limited 17 Novartis AG 18 Ono Pharmaceutical Co., Ltd. 19 PhaseBio Pharmaceuticals, Inc. 20 Trevena, Inc. 21 Acute Heart Failure - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 cenderitide - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 istaroxime - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 omecamtiv mecarbil MR - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 ONO-4232 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 PB-1046 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 ruboxistaurin - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 serelaxin - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 TRV-120023 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 ularitide - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Acute Heart Failure - Dormant Projects 55 Acute Heart Failure - Discontinued Products 56 Acute Heart Failure - Product Development Milestones 57 Featured News & Press Releases 57 Dec 11, 2015: Cardiorentis' Ularitide Receives FDA Fast Track Designation for the Treatment of Acute Decompensated Heart Failure 57 May 22, 2015: Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure 57 Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide 58 Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation 58 May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure 59 May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure 59 Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome 60 Mar 25, 2014: FDA Staff Says Novartis' Serelaxin Shouldn't Be Approved 60 Jan 24, 2014: Novartis Europharm's Reasanz Receives CHMP Negative Opinion 61 Jan 24, 2014: Novartis to request re-examination of serelaxin in acute heart failure for conditional marketing authorization in EU 62 Dec 02, 2013: Paladin Announces Filing of New Drug Submission for RLX030 (Serelaxin) 63 Sep 03, 2013: Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil 63 Sep 02, 2013: Novartis' serelaxin improved symptoms and mortality across multiple subgroups of patients with acute heart failure 65 Jun 21, 2013: Novartis's Serelaxin Receives FDA Breakthrough Therapy Designation For Acute Heart Failure 66 Mar 18, 2013: Cytokinetics Announces Update To Heart Failure Program 66 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 69 Disclaimer 70
List of Tables
Number of Products under Development for Acute Heart Failure, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Acute Heart Failure - Pipeline by Amgen Inc., H2 2016 14 Acute Heart Failure - Pipeline by Capricor Therapeutics, Inc., H2 2016 15 Acute Heart Failure - Pipeline by Eli Lilly and Company, H2 2016 16 Acute Heart Failure - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 17 Acute Heart Failure - Pipeline by Novartis AG, H2 2016 18 Acute Heart Failure - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 19 Acute Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016 20 Acute Heart Failure - Pipeline by Trevena, Inc., H2 2016 21 Assessment by Monotherapy Products, H2 2016 22 Number of Products by Stage and Target, H2 2016 24 Number of Products by Stage and Mechanism of Action, H2 2016 26 Number of Products by Stage and Route of Administration, H2 2016 28 Number of Products by Stage and Molecule Type, H2 2016 30 Acute Heart Failure - Dormant Projects, H2 2016 55 Acute Heart Failure - Discontinued Products, H2 2016 56



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify